US949A
(en)
|
|
1838-09-27 |
|
Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton |
US510A
(en)
|
|
1837-12-07 |
|
soeel |
US5863A
(en)
|
|
1848-10-17 |
|
Matthias p |
US5861A
(en)
|
|
1848-10-17 |
|
Locking umbrella and parasol |
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
GB1051218A
(es)
|
1963-03-09 |
|
|
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US5034393A
(en)
|
1989-07-27 |
1991-07-23 |
Dowelanco |
Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives
|
US5534520A
(en)
|
1990-04-10 |
1996-07-09 |
Fisher; Abraham |
Spiro compounds containing five-membered rings
|
US5852029A
(en)
|
1990-04-10 |
1998-12-22 |
Israel Institute For Biological Research |
Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
|
US5407938A
(en)
|
1990-04-10 |
1995-04-18 |
Israel Institute For Biological Research |
Certain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
|
US5326776A
(en)
|
1992-03-02 |
1994-07-05 |
Abbott Laboratories |
Angiotensin II receptor antagonists
|
WO1993017682A1
(en)
|
1992-03-04 |
1993-09-16 |
Abbott Laboratories |
Angiotensin ii receptor antagonists
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
EP0583861A1
(en)
|
1992-08-14 |
1994-02-23 |
Pioneer Electronic Corporation |
Organic electroluminescene device
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
US5654307A
(en)
|
1994-01-25 |
1997-08-05 |
Warner-Lambert Company |
Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
TW414798B
(en)
|
1994-09-07 |
2000-12-11 |
Thomae Gmbh Dr K |
Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
CA2218503C
(en)
|
1995-04-20 |
2001-07-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
US6395733B1
(en)
|
1995-06-07 |
2002-05-28 |
Pfizer Inc |
Heterocyclic ring-fused pyrimidine derivatives
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
MX9709867A
(es)
|
1995-06-07 |
1998-03-31 |
Pfizer |
Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
PT780386E
(pt)
|
1995-12-20 |
2003-02-28 |
Hoffmann La Roche |
Inibidores de metaloprotease de matriz
|
ZA9756B
(en)
|
1996-01-16 |
1997-07-17 |
Warner Lambert Co |
Process for preparing 4,6-disubstituted pyrido[3,4-d]-pyrimidines
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608653A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
JP3195756B2
(ja)
|
1996-07-04 |
2001-08-06 |
公子 吉水 |
潤滑補助体
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
EP0912572B1
(en)
|
1996-07-13 |
2003-01-15 |
Glaxo Group Limited |
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
NZ333303A
(en)
|
1996-07-18 |
2000-06-23 |
Lawrence Alan Reiter |
Phosphinate based inhibitors of matrix metalloproteases
|
BR9711223A
(pt)
|
1996-08-23 |
1999-08-17 |
Pfizer |
Derivados de cido arilsulfonilamino-hidrox mico
|
US6413971B1
(en)
|
1996-11-27 |
2002-07-02 |
Pfizer Inc |
Fused bicyclic pyrimidine derivatives
|
AR009435A1
(es)
|
1996-12-16 |
2000-04-12 |
Yamanouchi Pharma Co Ltd |
Derivado de guanaidina n-[carbonil(heteroaril-substituida de 5 miembros)], un inhibidor del intercambiador de na+/h+ que comprende dicho derivado y usosen la fabricacion de medicamentos.
|
EP0950059B1
(en)
|
1997-01-06 |
2004-08-04 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
IL131042A
(en)
|
1997-02-03 |
2004-07-25 |
Pfizer Prod Inc |
Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
|
EP0966438A1
(en)
|
1997-02-07 |
1999-12-29 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
HUP0000657A3
(en)
|
1997-02-11 |
2000-10-30 |
Pfizer |
N-arylsulfonyl-piperidine, -morpholine hydroxamic acid derivatives and pharmaceutical compositions containing them
|
CN100408100C
(zh)
|
1997-07-29 |
2008-08-06 |
阿尔康实验室公司 |
含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
|
ES2216293T3
(es)
|
1997-08-08 |
2004-10-16 |
Pfizer Products Inc. |
Derivados de acido ariloxiarilsulfonilamino-hidroxamico.
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
WO1999033172A1
(fr)
|
1997-12-22 |
1999-07-01 |
Hitachi, Ltd. |
Systeme d'amplification de puissance et terminal de communication radio mobile
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
JP4462654B2
(ja)
|
1998-03-26 |
2010-05-12 |
ソニー株式会社 |
映像素材選択装置及び映像素材選択方法
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
AU776788C
(en)
|
1998-12-16 |
2005-10-27 |
Warner-Lambert Company |
Treatment of arthritis with MEK inhibitors
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
DE19911510A1
(de)
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
GB9906566D0
(en)
|
1999-03-23 |
1999-05-19 |
Zeneca Ltd |
Chemical compounds
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
EP1081137A1
(en)
|
1999-08-12 |
2001-03-07 |
Pfizer Products Inc. |
Selective inhibitors of aggrecanase in osteoarthritis treatment
|
US8889112B2
(en)
|
1999-09-16 |
2014-11-18 |
Ocularis Pharma, Llc |
Ophthalmic formulations including selective alpha 1 antagonists
|
IL139197A0
(en)
|
1999-10-29 |
2001-11-25 |
Pfizer Prod Inc |
Use of corticotropin releasing factor antagonists and related compositions
|
EP1234031B2
(en)
|
1999-11-30 |
2021-11-24 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
EP1149583A3
(en)
|
2000-04-13 |
2001-11-14 |
Pfizer Products Inc. |
Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
|
EP1301472B1
(en)
|
2000-07-19 |
2014-03-26 |
Warner-Lambert Company LLC |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
MXPA03000874A
(es)
|
2000-08-09 |
2003-06-06 |
Astrazeneca Ab |
Compuestos quimicos.
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
JP4458746B2
(ja)
|
2001-01-16 |
2010-04-28 |
グラクソ グループ リミテッド |
癌の治療方法
|
DE10115921A1
(de)
|
2001-03-30 |
2002-10-02 |
Boehringer Ingelheim Pharma |
Verfahren zur Herstellung von 4,6-Diaminopyrimido[5,4-d]pyrimidinen
|
EP1249451B1
(en)
|
2001-04-13 |
2006-06-21 |
Pfizer Products Inc. |
Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
|
EP1434579B1
(en)
|
2001-10-09 |
2011-06-08 |
Amgen Inc. |
Imidazole derivatives as antiinflammatory agents
|
ES2305435T3
(es)
|
2002-01-10 |
2008-11-01 |
Bayer Healthcare Ag |
Inhibidores de la rho-quinasa.
|
EA008379B1
(ru)
|
2002-02-01 |
2007-04-27 |
Ариад Джин Терапьютикс, Инк. |
Фосфорсодержащие соединения и их применения
|
US7799827B2
(en)
|
2002-03-08 |
2010-09-21 |
Eisai Co., Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
EP3000810B1
(en)
|
2002-03-13 |
2017-07-19 |
Array Biopharma, Inc. |
N3 alkylated benzimidazole derivative as mek inhibitor
|
WO2003097615A1
(en)
|
2002-05-17 |
2003-11-27 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
US20040146509A1
(en)
|
2002-07-25 |
2004-07-29 |
Zhihe Li |
Methods for improvement of lung function using TGF-beta inhibitors
|
CA2494367A1
(en)
|
2002-07-25 |
2004-02-05 |
Scios Inc. |
Methods for improvement of lung function using tgf-.beta. inhibitors
|
US7488823B2
(en)
|
2003-11-10 |
2009-02-10 |
Array Biopharma, Inc. |
Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
|
CA2508660C
(en)
|
2002-12-23 |
2013-08-20 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
US20060167026A1
(en)
|
2003-01-06 |
2006-07-27 |
Hiroyuki Nawa |
Antipsychotic molecular-targeting epithelial growth factor receptor
|
WO2007038613A2
(en)
|
2005-09-26 |
2007-04-05 |
The Regents Of The University Of California |
Selective serine/threonine kinase inhibitors
|
BRPI0410720A
(pt)
|
2003-05-27 |
2006-06-20 |
Pfizer Prod Inc |
quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
|
US6933289B2
(en)
|
2003-07-01 |
2005-08-23 |
Allergan, Inc. |
Inhibition of irritating side effects associated with use of a topical ophthalmic medication
|
ATE444732T1
(de)
|
2003-08-07 |
2009-10-15 |
Allergan Inc |
Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
|
US20050059744A1
(en)
|
2003-09-12 |
2005-03-17 |
Allergan, Inc. |
Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
|
KR101223914B1
(ko)
|
2003-11-21 |
2013-01-18 |
어레이 바이오파마 인크. |
Akt 단백질 키나제 억제제
|
JPWO2005080377A1
(ja)
|
2004-02-20 |
2007-10-25 |
キリンホールディングス株式会社 |
TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
|
US20060074102A1
(en)
|
2004-05-14 |
2006-04-06 |
Kevin Cusack |
Kinase inhibitors as therapeutic agents
|
US20060188498A1
(en)
|
2005-02-18 |
2006-08-24 |
Genentech, Inc. |
Methods of using death receptor agonists and EGFR inhibitors
|
US20090155247A1
(en)
|
2005-02-18 |
2009-06-18 |
Ashkenazi Avi J |
Methods of Using Death Receptor Agonists and EGFR Inhibitors
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
NZ563193A
(en)
|
2005-05-09 |
2010-05-28 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
GB0510139D0
(en)
|
2005-05-18 |
2005-06-22 |
Addex Pharmaceuticals Sa |
Novel compounds B1
|
KR101139038B1
(ko)
|
2005-06-28 |
2012-05-02 |
삼성전자주식회사 |
피리미도피리미딘 유도체 및 이를 이용한 유기 박막 트랜지스터
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
DK1912636T3
(da)
|
2005-07-21 |
2014-07-21 |
Ardea Biosciences Inc |
N-(arylamino)-sulfonamid-inhibitorer af mek
|
US7880004B2
(en)
|
2005-09-15 |
2011-02-01 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
US7547782B2
(en)
|
2005-09-30 |
2009-06-16 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
PL1971601T3
(pl)
|
2005-11-15 |
2010-03-31 |
Array Biopharma Inc |
Pochodne N4-fenylo-chinazolino-4-aminy i związki pokrewne jako inhibitory receptorowych kinaz tyrozynowych ErbB typu I do leczenia chorób cechujących się nadmierną proliferacją komórek
|
TW200730527A
(en)
|
2005-12-02 |
2007-08-16 |
Takeda Pharmaceuticals Co |
Fused heterocyclic compound
|
EP1971611B1
(en)
|
2005-12-21 |
2012-10-10 |
Abbott Laboratories |
Anti-viral compounds
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
JP2009527459A
(ja)
|
2006-02-23 |
2009-07-30 |
武田薬品工業株式会社 |
縮合窒素含有複素環化合物
|
US8129357B2
(en)
|
2006-04-07 |
2012-03-06 |
Academia Sinica |
Method of making and using an adenosine analogue
|
US7351434B2
(en)
|
2006-04-07 |
2008-04-01 |
Academia Sinica |
Therapeutic Gastrodia extracts
|
TWI399380B
(zh)
|
2006-12-20 |
2013-06-21 |
Abbott Lab |
抗病毒化合物
|
WO2008086462A2
(en)
|
2007-01-11 |
2008-07-17 |
Wyeth |
AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF β-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
|
CA2682504C
(en)
|
2007-04-05 |
2012-10-30 |
Amgen Inc. |
Aurora kinase modulators and method of use
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
US8633186B2
(en)
|
2007-06-08 |
2014-01-21 |
Senomyx Inc. |
Modulation of chemosensory receptors and ligands associated therewith
|
ES2437327T3
(es)
|
2007-06-18 |
2014-01-10 |
Merck Sharp & Dohme B.V. |
Anticuerpos para el receptor PD-1 humano de muerte programada
|
JP2009046453A
(ja)
|
2007-08-22 |
2009-03-05 |
Takeda Chem Ind Ltd |
縮合複素環化合物
|
TWI471134B
(zh)
|
2007-09-12 |
2015-02-01 |
Genentech Inc |
肌醇磷脂3-激酶抑制劑化合物及化療劑之組合及使用方法
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
US7989465B2
(en)
|
2007-10-19 |
2011-08-02 |
Avila Therapeutics, Inc. |
4,6-disubstituted pyrimidines useful as kinase inhibitors
|
US7982036B2
(en)
|
2007-10-19 |
2011-07-19 |
Avila Therapeutics, Inc. |
4,6-disubstitued pyrimidines useful as kinase inhibitors
|
EP2214675B1
(en)
|
2007-10-25 |
2013-11-20 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
US7829574B2
(en)
|
2008-05-09 |
2010-11-09 |
Hutchison Medipharma Enterprises Limited |
Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
|
CN101575333B
(zh)
|
2008-05-09 |
2011-06-22 |
和记黄埔医药(上海)有限公司 |
一种喹唑啉衍生物及其医药用途
|
CA2723617A1
(en)
|
2008-05-14 |
2009-11-19 |
Amgen Inc. |
Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
AR073501A1
(es)
|
2008-09-08 |
2010-11-10 |
Boehringer Ingelheim Int |
Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
SI2342226T1
(sl)
|
2008-09-26 |
2016-11-30 |
Dana-Farber Cancer Institute Inc. |
Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
|
WO2010042489A2
(en)
|
2008-10-06 |
2010-04-15 |
Emory University |
Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use
|
WO2010045095A1
(en)
|
2008-10-14 |
2010-04-22 |
Ning Xi |
Compounds and methods of use
|
MX2011004535A
(es)
|
2008-10-29 |
2011-11-18 |
Deciphera Pharmaceuticals Llc |
Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
JP2012513409A
(ja)
|
2008-12-23 |
2012-06-14 |
アボット・ラボラトリーズ |
抗ウイルス化合物
|
CN101759683B
(zh)
|
2008-12-25 |
2011-12-28 |
哈尔滨誉衡药业股份有限公司 |
二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用
|
CA2752265A1
(en)
|
2009-02-17 |
2010-08-26 |
Boehringer Ingelheim International Gmbh |
Pyrimido [5,4-d] pyrimidine derivatives for the inhibition of tyrosine kinases
|
JP2013512251A
(ja)
|
2009-11-24 |
2013-04-11 |
アンプリミューン、インコーポレーテッド |
Pd−l1/pd−l2の同時阻害
|
CA2992770A1
(en)
|
2009-11-24 |
2011-06-03 |
Medimmune Limited |
Targeted binding agents against b7-h1
|
CN102086211B
(zh)
|
2009-12-08 |
2013-09-11 |
广东东阳光药业有限公司 |
作为蛋白激酶抑制剂的芳杂环化合物
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
US20110312996A1
(en)
|
2010-05-17 |
2011-12-22 |
Intermune, Inc. |
Novel inhibitors of hepatitis c virus replication
|
EP3363499A1
(en)
|
2010-06-11 |
2018-08-22 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-tim-3 antibody
|
US8299117B2
(en)
|
2010-06-16 |
2012-10-30 |
Metabolex Inc. |
GPR120 receptor agonists and uses thereof
|
CA2801182A1
(en)
|
2010-06-16 |
2011-12-22 |
Metabolex, Inc. |
Gpr120 receptor agonists and uses thereof
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
KR101538707B1
(ko)
|
2010-07-14 |
2015-07-22 |
베타 파머수티컬 컴퍼니 리미티드 |
c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체
|
CN102558147B
(zh)
|
2010-12-23 |
2014-09-17 |
江苏先声药物研究有限公司 |
化合物、制备方法及应用
|
US20130023531A1
(en)
|
2011-01-27 |
2013-01-24 |
Boehringer Ingelheim International Gmbh |
Pyrimido[5,4-d]pyrimidylamino phenyl sulfonamides as serine/threonine kinase inhibitors
|
WO2012125668A1
(en)
|
2011-03-17 |
2012-09-20 |
Merck Sharp & Dohme Corp. |
TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
|
RS57324B1
(sr)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
EP2734551B1
(en)
|
2011-07-24 |
2018-01-10 |
Cure Tech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
WO2013033981A1
(zh)
|
2011-09-06 |
2013-03-14 |
江苏先声药物研究有限公司 |
一类2,7-萘啶衍生物及其制备方法和应用
|
EA036814B9
(ru)
|
2011-11-28 |
2021-12-27 |
Мерк Патент Гмбх |
Антитело против pd-l1 (варианты), композиция, содержащая это антитело, и их применение
|
TW201336847A
(zh)
|
2012-02-07 |
2013-09-16 |
Taiho Pharmaceutical Co Ltd |
喹啉基吡咯并嘧啶化合物或其鹽
|
WO2013125211A1
(ja)
|
2012-02-22 |
2013-08-29 |
コニカミノルタ株式会社 |
光学フィルム、円偏光板および画像表示装置
|
HUE029343T2
(en)
|
2012-02-23 |
2017-02-28 |
Taiho Pharmaceutical Co Ltd |
Quinolylpyrrolo-pyrimidyl fused ring compounds and salts thereof
|
CA2872030A1
(en)
|
2012-05-31 |
2013-12-05 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-l1
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
CN104936982B
(zh)
|
2012-08-03 |
2020-04-24 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
MX370848B
(es)
|
2012-10-04 |
2020-01-08 |
Dana Farber Cancer Inst Inc |
Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
NZ711355A
(en)
|
2013-03-15 |
2020-06-26 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 binding proteins
|
CN105339389B
(zh)
|
2013-05-02 |
2021-04-27 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
US20140336182A1
(en)
|
2013-05-13 |
2014-11-13 |
Amgen Inc. |
Aurora Kinase Modulators and Method of Use
|
JP6563906B2
(ja)
|
2013-05-31 |
2019-08-21 |
ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. |
Pd−1に結合する抗原結合蛋白質
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
BR112016003247B1
(pt)
|
2013-08-22 |
2022-05-10 |
Taiho Pharmaceutical Co., Ltd |
Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
|
BR112016005408B1
(pt)
|
2013-09-13 |
2023-03-21 |
Beigene Switzerland Gmbh |
Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral
|
AU2014339900B2
(en)
|
2013-10-25 |
2019-10-24 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
WO2015085238A1
(en)
|
2013-12-05 |
2015-06-11 |
The Regents Of The University Of California, A California Corporation |
Inhibitors of lpxc
|
JP6483697B2
(ja)
|
2013-12-09 |
2019-03-13 |
ユーシービー バイオファルマ エスピーアールエル |
Tnf活性のモジュレーターとしての縮合二環式ヘテロ芳香族誘導体
|
ES2746805T3
(es)
|
2013-12-12 |
2020-03-06 |
Shanghai hengrui pharmaceutical co ltd |
Anticuerpo de PD-1, fragmento de unión a antígeno del mismo y aplicación médica del mismo
|
JP2017509319A
(ja)
|
2014-01-15 |
2017-04-06 |
カドモン コーポレイション,リミティド ライアビリティ カンパニー |
免疫調節剤
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
EP3556775B1
(en)
|
2014-01-28 |
2021-11-17 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
RS62618B1
(sr)
|
2014-01-31 |
2021-12-31 |
Daiichi Sankyo Co Ltd |
Anti-her2 antitelo-lek konjugat
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
JP6568926B2
(ja)
|
2014-03-20 |
2019-08-28 |
カペラ セラピューティクス,インコーポレーテッド |
癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
|
JP6468611B2
(ja)
|
2014-05-13 |
2019-02-13 |
アリアド ファーマシューティカルズ, インコーポレイテッド |
キナーゼ阻害のためのヘテロアリール化合物
|
DK3149042T3
(da)
|
2014-05-29 |
2019-11-04 |
Spring Bioscience Corp |
PD-L1-antistoffer og anvendelser deraf
|
MA40240B1
(fr)
|
2014-06-19 |
2019-03-29 |
Ariad Pharma Inc |
Composés hétéroaryle d'inhibition de la kinase
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
EP3160505A4
(en)
|
2014-07-03 |
2018-01-24 |
BeiGene, Ltd. |
Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
LT3215532T
(lt)
|
2014-11-06 |
2020-01-10 |
F. Hoffmann-La Roche Ag |
Anti-tim3 antikūnai ir jų naudojimo būdai
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
WO2016110821A1
(en)
|
2015-01-08 |
2016-07-14 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
WO2016128908A1
(en)
|
2015-02-12 |
2016-08-18 |
Advinus Therapeutics Limited |
Bicyclic compounds, compositions and medicinal applications thereof
|
JP2018510151A
(ja)
|
2015-03-06 |
2018-04-12 |
ソレント・セラピューティクス・インコーポレイテッド |
Tim3に結合する抗体医薬
|
MA41867A
(fr)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
GB201505658D0
(en)
|
2015-04-01 |
2015-05-13 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
CN104876912B
(zh)
|
2015-04-08 |
2017-07-21 |
苏州云轩医药科技有限公司 |
Wnt信号通路抑制剂及其应用
|
WO2016183278A1
(en)
|
2015-05-13 |
2016-11-17 |
Ariad Pharmaceuticals, Inc. |
Heteroaryl compounds for kinase inhibition
|
US20180117053A1
(en)
|
2015-05-27 |
2018-05-03 |
Metastat, Inc. |
The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
|
TWI703150B
(zh)
|
2015-06-04 |
2020-09-01 |
美商庫拉腫瘤技術股份有限公司 |
用於抑制menin及mll蛋白之交互作用的方法及組合物
|
KR20180058832A
(ko)
|
2015-10-09 |
2018-06-01 |
베링거 인겔하임 인터내셔날 게엠베하 |
Mdm2-p53 억제제로서의 스피로[3h-인돌-3,2'-피롤리딘]-2(1h)-온 화합물 및 유도체
|
JP7094879B2
(ja)
|
2015-10-23 |
2022-07-04 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
がんを処置する使用のための複素環式pdk1インヒビター
|
EP4292650A3
(en)
|
2015-12-22 |
2024-02-28 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
CN108541255B
(zh)
|
2016-02-02 |
2019-06-14 |
深圳市塔吉瑞生物医药有限公司 |
一种甾体类化合物及包含该化合物的组合物及其用途
|
CN115057861A
(zh)
|
2016-03-01 |
2022-09-16 |
上海医药集团股份有限公司 |
一种含氮杂环化合物、制备方法、中间体、组合物和应用
|
WO2017202719A1
(en)
|
2016-05-23 |
2017-11-30 |
Boehringer Ingelheim International Gmbh |
New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
|
JOP20190073A1
(ar)
|
2016-10-31 |
2019-04-07 |
Taiho Pharmaceutical Co Ltd |
مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
|
CN108101905A
(zh)
|
2016-11-24 |
2018-06-01 |
中国科学院上海药物研究所 |
嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
|
US10898487B2
(en)
|
2016-12-22 |
2021-01-26 |
Boehringer Ingelheim International Gmbh |
Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
|
JP2020514370A
(ja)
|
2017-03-17 |
2020-05-21 |
キュアバック アーゲー |
組合せ抗癌療法のためのrnaワクチン及び免疫チェックポイント阻害剤
|
US20180303821A1
(en)
|
2017-04-24 |
2018-10-25 |
BraneQuest, Inc. |
Membrane active molecules
|
FR3066761B1
(fr)
|
2017-05-23 |
2020-10-30 |
Centre Nat Rech Scient |
Nouveaux composes inhibiteurs des canaux ioniques
|
CN109020957B
(zh)
|
2017-06-12 |
2023-01-13 |
南京天印健华医药科技有限公司 |
作为mnk抑制剂的杂环化合物
|
AU2018306726B2
(en)
|
2017-07-28 |
2023-08-03 |
Yale University |
Anticancer drugs and methods of making and using same
|
CA3074459A1
(en)
|
2017-08-31 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of egfr and/or her2 and methods of use
|
EP3676254A4
(en)
|
2017-08-31 |
2021-01-13 |
AbbVie Inc. |
ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
|
DK3677266T5
(da)
|
2017-09-01 |
2024-08-26 |
Taiho Pharmaceutical Co Ltd |
Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer
|
CN109422755B
(zh)
|
2017-09-01 |
2023-07-04 |
上海医药集团股份有限公司 |
一种含氮杂环化合物、制备方法、中间体、组合物和应用
|
WO2019067543A1
(en)
|
2017-09-26 |
2019-04-04 |
The Regents Of The University Of California |
COMPOSITIONS AND METHODS OF TREATING CANCER
|
EP3691642B1
(en)
|
2017-10-02 |
2024-03-06 |
Boehringer Ingelheim International GmbH |
[1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors
|
WO2019081486A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
4H-PYRROLO [3,2-C] PYRIDIN-4-ONE DERIVATIVES
|
TWI810230B
(zh)
|
2017-12-21 |
2023-08-01 |
德商百靈佳殷格翰國際股份有限公司 |
作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物
|
MA51672A
(fr)
|
2018-01-26 |
2020-12-02 |
Exelixis Inc |
Composés destinés au traitement des troubles kinases-dépendants
|
CN108490184B
(zh)
|
2018-01-26 |
2021-01-08 |
中国科学院化学研究所 |
人pot1蛋白在白血病诊断中的用途
|
TWI798334B
(zh)
|
2018-01-31 |
2023-04-11 |
大陸商迪哲(江蘇)醫藥股份有限公司 |
Erbb/btk抑制劑
|
WO2019162323A1
(en)
|
2018-02-21 |
2019-08-29 |
Boehringer Ingelheim International Gmbh |
New benzimidazole compounds and derivatives as egfr inhibitors
|
JP2021104931A
(ja)
|
2018-02-22 |
2021-07-26 |
大日本住友製薬株式会社 |
含窒素複素環を有するジベンゾアゼピン誘導体
|
AU2019223168B2
(en)
|
2018-02-23 |
2024-09-12 |
The Regents Of The University Of Michigan |
EGFR dimer disruptors and use of the same
|
JP7190755B2
(ja)
|
2018-03-06 |
2022-12-16 |
北京賽特明強医薬科技有限公司 |
オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
|
KR20190108079A
(ko)
|
2018-03-13 |
2019-09-23 |
보로노이바이오 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
|
KR20190108080A
(ko)
|
2018-03-13 |
2019-09-23 |
보로노이바이오 주식회사 |
2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물
|
WO2019214651A1
(zh)
|
2018-05-08 |
2019-11-14 |
南京明德新药研发有限公司 |
作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
|
TW202344253A
(zh)
|
2018-05-08 |
2023-11-16 |
大陸商迪哲(江蘇)醫藥股份有限公司 |
ErbB受體抑制劑
|
CA3099737A1
(en)
|
2018-05-14 |
2019-11-21 |
Ariad Pharmaceuticals, Inc. |
Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
|
EP3569618A1
(en)
|
2018-05-19 |
2019-11-20 |
Boehringer Ingelheim International GmbH |
Antagonizing cd73 antibody
|
US11485713B2
(en)
|
2018-05-25 |
2022-11-01 |
Essa Pharma, Inc. |
Androgen receptor modulators and methods for their use
|
CN111801328B
(zh)
|
2018-05-29 |
2023-06-02 |
四川海思科制药有限公司 |
自分泌运动因子抑制剂及其用途
|
US10711000B2
(en)
|
2018-05-29 |
2020-07-14 |
Fronthera U.S. Pharmaceuticals Llc |
Autotaxin inhibitors and uses thereof
|
AU2019287750A1
(en)
|
2018-06-14 |
2020-10-15 |
Dana-Farber Cancer Institute, Inc. |
Cyano quinoline amide compounds as HER2 inhibitors and methods of use
|
TW202012391A
(zh)
|
2018-07-04 |
2020-04-01 |
日商第一三共股份有限公司 |
二芳基醚型喹唑啉衍生物
|
US20210347785A1
(en)
|
2018-08-01 |
2021-11-11 |
Shanghai Ennovabio Pharmaceuticals Co., Ltd. |
Preparation and application of aromatic compound having immunoregulatory function
|
WO2020033413A2
(en)
|
2018-08-07 |
2020-02-13 |
Tosk, Inc. |
Modulators of ras gtpase
|
EP3833372A4
(en)
|
2018-08-10 |
2022-06-08 |
Blueprint Medicines Corporation |
TREATMENT OF EGFR MUTANT CANCER
|
EP4360713A3
(en)
|
2018-09-18 |
2024-05-22 |
F. Hoffmann-La Roche AG |
Quinazoline derivatives as antitumor agents
|
WO2020061470A1
(en)
|
2018-09-21 |
2020-03-26 |
Spectrum Pharmaceuticals, Inc. |
Novel quinazoline egfr inhibitors
|
CN113164776A
(zh)
|
2018-09-25 |
2021-07-23 |
黑钻治疗公司 |
酪氨酸激酶抑制剂组合物、其制备方法和使用方法
|
EP3856726A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
CN111171020A
(zh)
|
2018-11-13 |
2020-05-19 |
上海轶诺药业有限公司 |
一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
|
TWI741423B
(zh)
|
2018-11-30 |
2021-10-01 |
大陸商江蘇豪森藥業集團有限公司 |
雜芳類衍生物調節劑、其製備方法和應用
|
TWI837266B
(zh)
|
2018-12-28 |
2024-04-01 |
日商大鵬藥品工業股份有限公司 |
L718及/或l792突變型治療抗性egfr抑制劑
|
CA3133688A1
(en)
|
2019-03-15 |
2020-09-24 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
CN115838369A
(zh)
|
2019-03-19 |
2023-03-24 |
株式会社沃若诺伊 |
杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
|
CN109912572B
(zh)
|
2019-03-29 |
2020-11-06 |
武汉德诺美生物医药股份有限公司 |
Egfr抑制剂及其医药用途
|
PE20220254A1
(es)
|
2019-04-24 |
2022-02-16 |
Bayer Ag |
Compuestos de 4h-pirrolo[3,2-c]piridin-4-ona
|
AU2020261423A1
(en)
|
2019-04-25 |
2021-12-09 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of tyrosine kinase
|
CN112079830B
(zh)
|
2019-06-14 |
2023-12-22 |
上海翰森生物医药科技有限公司 |
含并环类衍生物抑制剂、其制备方法和应用
|
US20220380382A1
(en)
|
2019-06-24 |
2022-12-01 |
Boehringer Ingelheim International Gmbh |
New macrocyclic compounds and derivatives as egfr inhibitors
|
WO2021030711A1
(en)
|
2019-08-15 |
2021-02-18 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
CA3151355C
(en)
|
2019-09-26 |
2024-02-20 |
Yihan Wang |
Substituted aromatic fused ring derivative and composition comprising same, and use thereof
|
US20230027026A1
(en)
|
2019-09-27 |
2023-01-26 |
Jubilant Biosys Limited |
Fused pyrimidine compounds, compositions and medicinal applications thereof
|
CN115181104A
(zh)
|
2019-09-29 |
2022-10-14 |
深圳市塔吉瑞生物医药有限公司 |
取代的稠合三环衍生物及其组合物及用途
|
WO2021127456A1
(en)
|
2019-12-19 |
2021-06-24 |
Rain Therapeutics Inc. |
Methods of inhibiting epidermal growth factor receptor proteins
|
WO2021127397A1
(en)
|
2019-12-19 |
2021-06-24 |
Black Diamond Therapeutics, Inc. |
Nitrogen heterocyclic compounds and methods of use
|
BR112022012585A2
(pt)
|
2019-12-23 |
2022-09-27 |
Blueprint Medicines Corp |
Inibidores de formas mutantes de egfr
|
CN115052881B
(zh)
|
2020-02-03 |
2024-07-09 |
勃林格殷格翰国际有限公司 |
作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
|
EP4100409B1
(en)
|
2020-02-03 |
2024-08-28 |
Boehringer Ingelheim International GmbH |
[1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
|
CN113336760B
(zh)
|
2020-02-18 |
2022-11-04 |
深圳市塔吉瑞生物医药有限公司 |
取代的酰胺衍生物及其组合物及用途
|
WO2021179274A1
(en)
|
2020-03-13 |
2021-09-16 |
Suzhou Zanrong Pharma Ltd. |
ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
|
WO2021185348A1
(zh)
|
2020-03-20 |
2021-09-23 |
深圳市塔吉瑞生物医药有限公司 |
取代的丙烯酰胺衍生物及其组合物及用途
|
WO2021198020A1
(en)
|
2020-03-31 |
2021-10-07 |
Bayer Aktiengesellschaft |
3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
|
US11608343B2
(en)
|
2020-04-24 |
2023-03-21 |
Boehringer Ingelheim International Gmbh |
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
|
JP7519463B2
(ja)
|
2020-05-05 |
2024-07-19 |
ヌバレント, インク. |
ヘテロ芳香族大環状エーテル化学療法剤
|
EP4146205A4
(en)
|
2020-05-05 |
2024-05-29 |
Nuvalent, Inc. |
HETEROAROMATIC MACROCYCLIC ETHER-BASED CHEMOTHERAPY AGENTS
|
KR20210137305A
(ko)
|
2020-05-07 |
2021-11-17 |
삼성디스플레이 주식회사 |
유기 발광 소자 및 이를 포함한 전자 장치
|
WO2021231400A1
(en)
|
2020-05-12 |
2021-11-18 |
Accutar Biotechnology, Inc. |
Bis-aryl ethers containing n-acyl azetidine as egfr/her2 inhibitors
|
WO2021243596A1
(en)
|
2020-06-03 |
2021-12-09 |
InventisBio Co., Ltd. |
Aminopyrimidine compounds, preparation methods and uses thereof
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
CN113861195B
(zh)
|
2020-06-30 |
2022-11-18 |
上海和誉生物医药科技有限公司 |
一种多稠环egfr抑制剂及其制备方法和应用
|
CN113880804A
(zh)
|
2020-07-01 |
2022-01-04 |
微境生物医药科技(上海)有限公司 |
新型苯并咪唑化合物
|
WO2022006386A1
(en)
|
2020-07-02 |
2022-01-06 |
Enliven Therapeutics, Inc. |
Alkyne quinazoline derivatives as inhibitors of erbb2
|
WO2022007841A1
(zh)
|
2020-07-09 |
2022-01-13 |
上海和誉生物医药科技有限公司 |
一种egfr抑制剂、其制备方法和在药学上的应用
|
CN113943288A
(zh)
|
2020-07-17 |
2022-01-18 |
微境生物医药科技(上海)有限公司 |
5,6-二氢吡嗪并[2,3-c]异喹啉化合物
|
WO2022033416A1
(zh)
|
2020-08-10 |
2022-02-17 |
上海和誉生物医药科技有限公司 |
作为egfr抑制剂的稠环化合物及其制备方法和应用
|
AU2021326209B2
(en)
|
2020-08-10 |
2024-03-28 |
Abbisko Therapeutics Co., Ltd |
EFGR inhibitor, preparation method therefor, and application thereof
|
WO2022033455A1
(zh)
|
2020-08-13 |
2022-02-17 |
上海和誉生物医药科技有限公司 |
具有egfr抑制活性的三嗪衍生物及其制备方法和应用
|
WO2022037568A1
(en)
|
2020-08-17 |
2022-02-24 |
Betta Pharmaceuticals Co., Ltd |
Bicyclic compounds, compositions and use thereof
|
WO2022042755A1
(zh)
|
2020-08-28 |
2022-03-03 |
华东理工大学 |
抑制突变型egfr的化合物及其应用
|
US20230372346A1
(en)
|
2020-09-08 |
2023-11-23 |
Cullinan Pearl Corp. |
Treatment regimens for exon-20 insertion mutant egfr cancers
|
BR112023001864A2
(pt)
|
2020-09-14 |
2023-03-28 |
Boehringer Ingelheim Int |
Vacina de reforço primário heteróloga
|
TW202227425A
(zh)
|
2020-09-18 |
2022-07-16 |
南韓商沃若諾伊生物公司 |
雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物
|
MX2023003362A
(es)
|
2020-09-23 |
2023-05-30 |
Scorpion Therapeutics Inc |
Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer.
|
TW202229282A
(zh)
|
2020-09-30 |
2022-08-01 |
美商史考皮恩治療有限公司 |
治療癌症之方法
|
WO2022072632A1
(en)
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Bicyclic compounds for use in the treatment cancer
|
WO2022072645A2
(en)
|
2020-09-30 |
2022-04-07 |
Scorpion Therapeutics, Inc. |
Methods for treating cancer
|
EP4225300A1
(en)
|
2020-10-05 |
2023-08-16 |
Dana-Farber Cancer Institute, Inc. |
Potent and selective inhibitors of her2
|
WO2022076671A1
(en)
|
2020-10-08 |
2022-04-14 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers using quinazoline derivatives
|
US20240101576A1
(en)
|
2020-10-09 |
2024-03-28 |
Scorpion Therapeutics, Inc. |
Heterocyclic inhibitors of egfr and/or her2, for use in the treatment of cancer
|
JP2023545178A
(ja)
|
2020-10-14 |
2023-10-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Stingアゴニストと、細胞透過性ペプチド、カーゴ、及びtlrペプチドアゴニストを含む複合体との組合せ
|
WO2023077259A1
(en)
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
US20240051945A1
(en)
|
2020-10-30 |
2024-02-15 |
Blueprint Medicines Corporation |
Pyrimidine compounds, compositions, and medicinal applications thereof
|
JP2023549074A
(ja)
|
2020-10-30 |
2023-11-22 |
ブループリント メディシンズ コーポレイション |
ピリミジン化合物、組成物、及びその医薬用途
|
WO2022094271A1
(en)
|
2020-10-30 |
2022-05-05 |
Scorpion Therapeutics, Inc. |
Methods for treating cancer
|
US12064421B2
(en)
|
2020-11-02 |
2024-08-20 |
Boehringer Ingelheim International Gmbh |
Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
|
WO2022098992A1
(en)
|
2020-11-05 |
2022-05-12 |
Scorpion Therapeutics, Inc. |
Use of macrocyclic compounds in methods of treating cancer
|
CA3201333A1
(en)
|
2020-11-11 |
2022-05-19 |
Bayer Aktiengesellschaft |
N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer
|
CN114539226A
(zh)
|
2020-11-19 |
2022-05-27 |
上海翰森生物医药科技有限公司 |
一种含吲哚类衍生物自由碱的晶型及其制备方法和应用
|
TW202222795A
(zh)
|
2020-11-19 |
2022-06-16 |
大陸商上海翰森生物醫藥科技有限公司 |
一種含吲哚類衍生物的鹽、晶型及其製備方法和應用
|
WO2022105908A1
(zh)
|
2020-11-23 |
2022-05-27 |
上海和誉生物医药科技有限公司 |
Egfr抑制剂及其制备方法与在药学上的应用
|
CN115867539A
(zh)
|
2020-12-02 |
2023-03-28 |
上海和誉生物医药科技有限公司 |
2,3-二氢-1H-吡咯并[3,2-b]吡啶衍生物、其制备方法和应用
|
CN114621207A
(zh)
|
2020-12-11 |
2022-06-14 |
广东东阳光药业有限公司 |
一种作为甲状腺激素β受体激动剂的化合物及其用途
|
WO2022139386A1
(ko)
|
2020-12-21 |
2022-06-30 |
주식회사 비투에스바이오 |
헤테로아릴 유도체 화합물 및 이의 용도
|
WO2022140769A1
(en)
|
2020-12-22 |
2022-06-30 |
Enliven Therapeutics, Inc. |
Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
|
KR20220097305A
(ko)
|
2020-12-29 |
2022-07-07 |
주식회사 비투에스바이오 |
헤테로아릴 유도체 화합물 및 이의 용도
|
UY39593A
(es)
|
2020-12-29 |
2022-07-29 |
Spectrum Pharmaceuticals Inc |
Tratamiento para tumores sólidos malignos
|
CN114874189B
(zh)
|
2021-02-05 |
2023-09-29 |
深圳市塔吉瑞生物医药有限公司 |
取代的杂芳基衍生物及其组合物及用途
|
WO2022170043A1
(en)
|
2021-02-05 |
2022-08-11 |
Accutar Biotechnology, Inc. |
Quinazoline derived compounds as egfr inhibitors and their uses thereof
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
WO2022171138A1
(zh)
|
2021-02-10 |
2022-08-18 |
上海医药集团股份有限公司 |
一种含氮杂环化合物的晶型、其制备方法及应用
|
UY39662A
(es)
|
2021-03-10 |
2022-09-30 |
Blueprint Medicines Corp |
Inhibidores de egfr
|
CA3211588A1
(en)
|
2021-03-11 |
2022-09-15 |
Sung Eun Kim |
Novel pyrimidine derivative showing inhibition effect on growth of cancer cells
|
TW202300148A
(zh)
|
2021-03-17 |
2023-01-01 |
大陸商江蘇恒瑞醫藥股份有限公司 |
喜樹鹼衍生物的製備方法
|
WO2022197913A1
(en)
|
2021-03-18 |
2022-09-22 |
Scorpion Therapeutics, Inc. |
Bicyclic derivatives which can be used to treat cancer
|
AU2022235956A1
(en)
|
2021-03-19 |
2023-10-05 |
Beijing Scitech-Mq Pharmaceuticals Limited |
Quinazoline-based compound, composition, and application of quinazoline-based compound
|
WO2022212538A1
(en)
|
2021-03-31 |
2022-10-06 |
Blueprint Medicines Corporation |
Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
|
JP2024514098A
(ja)
|
2021-04-01 |
2024-03-28 |
シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド |
ErbB2突然変異体を標的とする阻害薬の調製における化合物の使用
|
WO2022221227A1
(en)
*
|
2021-04-13 |
2022-10-20 |
Nuvalent, Inc. |
Amino-substituted heterocycles for treating cancers with egfr mutations
|
JP2024515204A
(ja)
|
2021-04-22 |
2024-04-05 |
ボロノイ インコーポレイテッド |
ヘテロアリール誘導体化合物およびその用途
|
EP4335847A1
(en)
|
2021-05-07 |
2024-03-13 |
Voronoi Inc. |
Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient
|
WO2022237825A1
(zh)
|
2021-05-13 |
2022-11-17 |
上海和誉生物医药科技有限公司 |
具有egfr抑制活性的氮杂芳基衍生物、其制备方法和应用
|
WO2022245085A1
(ko)
|
2021-05-17 |
2022-11-24 |
보로노이바이오 주식회사 |
헤테로아릴 유도체 화합물 및 이의 용도
|
JP2024520461A
(ja)
|
2021-05-24 |
2024-05-24 |
大鵬薬品工業株式会社 |
Egfr及び/又はher2に異常を有するがんを有する対象の治療方法
|
BR112023025194A2
(pt)
|
2021-06-04 |
2024-02-27 |
Boehringer Ingelheim Int |
Anticorpos anti-sirp-alfa
|
WO2022266426A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
6-(heterocycloalkyl-oxy)-quinazoline derivatives and uses thereof
|
WO2022266458A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
6-heterocycloalkyl-quinazoline derivatives and uses thereof
|
WO2022266425A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
3-cyano-quinoline derivatives and uses thereof
|
WO2022266427A1
(en)
|
2021-06-17 |
2022-12-22 |
Black Diamond Therapeutics, Inc. |
4-(aryl-methyl-amino)-quinazoline derivatives and uses thereof
|
US20240299387A1
(en)
|
2021-06-22 |
2024-09-12 |
Blueprint Medicines Corporation |
Heterocyclic egfr inhibitors for use in the treatment of cancer
|
WO2022271613A1
(en)
|
2021-06-22 |
2022-12-29 |
Blueprint Medicines Corporation |
Heterocyclic egfr inhibitors for use in the treatment of cancer
|
WO2022271630A1
(en)
|
2021-06-22 |
2022-12-29 |
Blueprint Medicines Corporation |
Egfr inhibitors
|
WO2022271612A1
(en)
|
2021-06-22 |
2022-12-29 |
Blueprint Medicines Corporation |
Heterocyclic egfr inhibitors for use in the treatment of cancer
|
US20240293404A1
(en)
|
2021-06-23 |
2024-09-05 |
Blueprint Medicines Corporation |
Salt and crystal forms of an epidermal growth factor receptor inhibitor
|
AR126196A1
(es)
|
2021-06-23 |
2023-09-27 |
Blueprint Medicines Corp |
Proceso para preparar inhibidores de egfr
|
MX2023015139A
(es)
|
2021-06-26 |
2024-01-22 |
Array Biopharma Inc |
Inhibidores de mutacion de her2.
|
EP4371983A1
(en)
|
2021-07-13 |
2024-05-22 |
Korea Research Institute of Chemical Technology |
Novel pyrimidine-2,4-diamine derivatives, preparation method therefor, and pharmaceutical composition containing same as active ingredient for prevention or treatment of cancer
|
WO2023015240A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Tricyclic fused pyrimidine compounds for use as her2 inhibitors
|
MX2024001630A
(es)
|
2021-08-05 |
2024-03-15 |
Korea Res Inst Chemical Tech |
Derivado de pirimidina, metodo para preparar el mismo y composicion farmaceutica para prevenir o tratar el cancer que comprende el mismo como ingrediente activo.
|
EP4382511A1
(en)
|
2021-08-06 |
2024-06-12 |
Abbisko Therapeutics Co., Ltd. |
Pyrimidine or pyridine derivative, preparation method therefor, and application thereof in pharmacy
|
KR20240069728A
(ko)
|
2021-08-24 |
2024-05-20 |
아쓰로시 테라퓨틱스, 인크. |
질환의 치료를 위한 퀴나졸린 화합물
|
CA3231608A1
(en)
|
2021-10-01 |
2023-04-06 |
Amit M. Deshpande |
Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
|
CA3231813A1
(en)
|
2021-10-01 |
2023-04-06 |
Sibao CHEN |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
MX2024004738A
(es)
|
2021-10-20 |
2024-05-14 |
Hoffmann La Roche |
Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas.
|
WO2023081637A1
(en)
|
2021-11-02 |
2023-05-11 |
Enliven Therapeutics, Inc. |
Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
|
US20230227470A1
(en)
|
2021-12-01 |
2023-07-20 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
WO2023099624A1
(en)
|
2021-12-01 |
2023-06-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
TW202340209A
(zh)
|
2021-12-01 |
2023-10-16 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
WO2023099608A1
(en)
|
2021-12-01 |
2023-06-08 |
Boehringer Ingelheim International Gmbh |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
WO2023154124A1
(en)
|
2022-02-09 |
2023-08-17 |
Enliven Therapeutics, Inc. |
Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2
|
WO2023173083A1
(en)
|
2022-03-11 |
2023-09-14 |
Scorpion Therapeutics, Inc. |
Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer
|
AU2023243776A1
(en)
|
2022-03-28 |
2024-09-12 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
|
WO2023195773A1
(ko)
|
2022-04-05 |
2023-10-12 |
보로노이 주식회사 |
헤테로아릴 유도체 및 이의 용도
|